Skip to main content

Advertisement

SpringerLink
Log in

MOG-IgG Associated Disease (MOG-AD) in Adults

  • Neurologic Ophthalmology and Otology (R Shin and D Gold, Section Editors)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

This review offers a look into available treatment strategies for patients with MOG-IgG associated disease (MOG-AD). We will focus on evidence-based management options in the acute setting. We will also present recommendations for initiation of long-term immunotherapy for patients with a relapsing course and discuss our approach for monitoring disease progression and escalation of therapy.

Recent findings

As commercial testing for MOG-IgG did not become widely available until 2016, most of the evidence concerning management is from retrospective observational studies. Acutely, 1 g daily of intravenous methylprednisolone (IVMP) for 3–5 days has been associated with better outcomes for optic neuritis. This is typically followed by a prolonged oral prednisone taper. Long-term immunotherapy is reserved for patients with relapsing or severely disabling disease. There are yet to be any prospective trials for selection of the most appropriate agent. Rituximab, azathioprine, mycophenolate mofetil, and IVIG have all been used. Disease-modifying therapies (DMTs) typically used for multiple sclerosis (MS) are avoided.

Summary

IVMP followed by a prolonged prednisone taper is the mainstay of acute management. However, there is limited consensus on the best long-term immunotherapy and prospective studies are needed to compare the efficacy of different agents. The development of targeted therapies is expected in the future as the pathogenesis of MOG-IgG becomes better understood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89–102. https://doi.org/10.1038/s41582-018-0112-x A review of MOG-AD, with focus on molecular, radiological, and clinical aspects.

    Article  CAS  PubMed  Google Scholar 

  2. Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017;8(529). https://doi.org/10.3389/fimmu.2017.00529.

  3. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Jorge FMDH, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474–81. https://doi.org/10.1212/wnl.0000000000000101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol. 2014;71(3):276–83. https://doi.org/10.1001/jamaneurol.2013.5857.

    Article  PubMed  Google Scholar 

  5. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79(12):1273–7. https://doi.org/10.1212/wnl.0b013e31826aac4e.

    Article  CAS  PubMed  Google Scholar 

  6. • Juryńczyk M, Jacob A, Fujihara K, Palace J. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol. 2019;19(3):187. https://doi.org/10.1136/practneurol-2017-001787 A review of MOG-AD with focus on practical aspects, such as diagnosis, treatment, and prognosis.

    Article  PubMed  Google Scholar 

  7. •• Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. https://doi.org/10.1186/s12974-016-0718-0 Part 2 of 4 of a large multicenter retrospective study of MOG-AD. This part focuses on clinical presentation, radiological features, treatment, and outcomes.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016;263(7):1349–60. https://doi.org/10.1007/s00415-016-8147-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cobo-Calvo Á, Ruiz A, D’Indy H, Poulat A-L, Carneiro M, Philippe N, et al. MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017;264(9):1945–55. https://doi.org/10.1007/s00415-017-8583-z.

    Article  CAS  PubMed  Google Scholar 

  10. • Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016;13(1). https://doi.org/10.1186/s12974-016-0719-z. Part 3 of 4 of a large multicenter retrospective study of MOG-AD. This part focuses on brainstem presentations as part of the MOG-AD spectrum.

  11. •• Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology. 2018;90(21):e1858–e69. https://doi.org/10.1212/wnl.0000000000005560 A large cohort of MOG-AD patients, illustrating the wide spectrum of MOG-AD.

    Article  CAS  PubMed  Google Scholar 

  12. •• Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128–38. https://doi.org/10.1093/brain/awx276 One of the largest MOG-AD cohort studies, which outlined the clinical presentation of MOG-AD and differentiated it from MS.

    Article  PubMed  Google Scholar 

  13. •• Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13(1). https://doi.org/10.1186/s12974-016-0717-1. Part 1 of 4 of a large multicenter retrospective study of MOG-AD. This part explores the course of disease and outcomes. It also provides a comparison to AQP4-seropositive NMOSD.

  14. • Cobo-Calvo A, Sepúlveda M, D’Indy H, Armangué T, Ruiz A, Maillart E, et al. Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. J Neurol. 2019;266(4):806–15. https://doi.org/10.1007/s00415-018-9160-9 An analysis of MOG-IgG titers throughout the course of MOG-AD and explores a correlation with clinical presentation and risk of future relapses.

    Article  PubMed  Google Scholar 

  15. Ramanathan S, Reddel SW, Henderson A, Parratt JDE, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation. 2014;1(4):e40. https://doi.org/10.1212/nxi.0000000000000040.

    Article  Google Scholar 

  16. •• Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127–37. https://doi.org/10.1136/jnnp-2017-316880 A retrospective study demonstrating the large clinical spectrum of MOG-AD and comparison of different immunotherapies.

    Article  PubMed  Google Scholar 

  17. Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson APD, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler J. 2015;22(4):470–82. https://doi.org/10.1177/1352458515593406.

    Article  CAS  Google Scholar 

  18. • Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga AS, Fryer JP, Leavitt JA, et al. Myelin oligodendrocyte glycoprotein antibody–positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8–15. https://doi.org/10.1016/j.ajo.2018.07.020 A large study focusing on MOG-AD optic neuritis, with focus on its specific clinical and radiological features.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2015. https://doi.org/10.1136/jnnp-2014-310206.

  20. Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflammation. 2015;2(6):e163. https://doi.org/10.1212/nxi.0000000000000163.

    Article  Google Scholar 

  21. Havla J, Kümpfel T, Schinner R, Spadaro M, Schuh E, Meinl E, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017;264(1):139–51. https://doi.org/10.1007/s00415-016-8333-7.

    Article  CAS  PubMed  Google Scholar 

  22. Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflammation. 2019;6(4):e572. https://doi.org/10.1212/NXI.0000000000000572.

    Article  Google Scholar 

  23. • Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13(1). https://doi.org/10.1186/s12974-016-0720-6. Part 4 of 4 of a large multicenter restrospective study of MOG-AD. This part focuses on optic neuritis, and compares the MOG-AD features with those of AQP4-seropositive optic neuritis.

  24. Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, et al. Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody–associated optic neuritis. J Neuroophthalmol. 2019;39(1):3–7. https://doi.org/10.1097/wno.0000000000000669.

    Article  PubMed  Google Scholar 

  25. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8(1):184. https://doi.org/10.1186/1742-2094-8-184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Waters P, Woodhall M, O'Connor KC, Reindl M, Lang B, Sato DK, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflammation. 2015;2(3):e89. https://doi.org/10.1212/nxi.0000000000000089.

    Article  Google Scholar 

  27. • Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9. https://doi.org/10.3389/fneur.2018.00888. A thorough review of diagnosis and treatment of MOG-AD and NMOSD, with good comparison between the two entities.

  28. • Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. https://doi.org/10.1186/s12974-018-1144-2 Expert panel recommendations for the diagnosis and antibody testing for MOG-AD.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89. https://doi.org/10.1212/wnl.0000000000001729.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Nakajima H, Motomura M, Tanaka K, Fujikawa A, Nakata R, Maeda Y, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5(4):e007766-e. https://doi.org/10.1136/bmjopen-2015-007766.

    Article  Google Scholar 

  31. Akaishi T, Sato DK, Takahashi T, Nakashima I. Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. Neurochem Int. 2019;130:104319. https://doi.org/10.1016/j.neuint.2018.10.016.

    Article  CAS  PubMed  Google Scholar 

  32. Kezuka T, Ishikawa H. Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol. 2018;62(2):101–8. https://doi.org/10.1007/s10384-018-0561-1.

    Article  CAS  PubMed  Google Scholar 

  33. Hyun J-W, Woodhall MR, Kim S-H, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811. https://doi.org/10.1136/jnnp-2017-315998.

    Article  PubMed  Google Scholar 

  34. Costa BK, Passos GR, Becker J, Sato DK. MOG-IgG associated optic neuritis is not multiple sclerosis. Arq Neuropsiquiatr. 2017;75:687–91.

    Article  Google Scholar 

  35. Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation. 2015;2(4):e131. https://doi.org/10.1212/nxi.0000000000000131.

    Article  Google Scholar 

  36. Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33(1):47–54. https://doi.org/10.1097/wco.0000000000000766.

    Article  CAS  PubMed  Google Scholar 

  37. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K-D, Wegner B, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206–16. https://doi.org/10.1002/ana.24554.

    Article  CAS  PubMed  Google Scholar 

  38. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K-D, Hellwig K, et al. Apheresis therapies for NMOSD attacks. Neurol Neuroimmunol Neuroinflammation. 2018;5(6):e504. https://doi.org/10.1212/NXI.0000000000000504.

    Article  Google Scholar 

  39. Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol. 2019;266(5):1280–6. https://doi.org/10.1007/s00415-018-9122-2.

    Article  PubMed  Google Scholar 

  40. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58(1):143–6. https://doi.org/10.1212/WNL.58.1.143.

    Article  CAS  PubMed  Google Scholar 

  41. Bonnan M, Valentino R, Debeugny S, Merle H, Fergé J-L, Mehdaoui H, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346. https://doi.org/10.1136/jnnp-2017-316286.

    Article  PubMed  Google Scholar 

  42. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion. 2003;34(10):891–4. https://doi.org/10.1046/j.1537-2995.1994.341095026976.x.

    Article  Google Scholar 

  43. Tajfirouz DA, Bhatti MT, Chen JJ. Clinical characteristics and treatment of MOG-IgG–associated optic neuritis. Curr Neurol Neurosci Rep. 2019;19(12):100. https://doi.org/10.1007/s11910-019-1014-z.

    Article  CAS  PubMed  Google Scholar 

  44. Tsantes E, Curti E, Siena E, Granella F. Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease. Mult Scler Relat Disord. 2019;32:27–9. https://doi.org/10.1016/j.msard.2019.04.021.

    Article  PubMed  Google Scholar 

  45. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga AS, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000009758.

  46. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–8. https://doi.org/10.1016/j.tmrv.2013.05.004.

    Article  PubMed  Google Scholar 

  47. López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG–associated disorders. JAMA Neurol. 2018;75(11):1355–63. https://doi.org/10.1001/jamaneurol.2018.1814.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, et al. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol. 2017;264(12):2420–30. https://doi.org/10.1007/s00415-017-8635-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Cobo Calvo A, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler J. 2015;21(7):866–74. https://doi.org/10.1177/1352458514555785.

    Article  CAS  Google Scholar 

  50. Jitprapaikulsan J, Fryer JP, Majed M, Smith CY, Jenkins SM, Cabre P, et al. Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflammation. 2020;7(4):e727. https://doi.org/10.1212/nxi.0000000000000727.

    Article  Google Scholar 

  51. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1–16. https://doi.org/10.1007/s00415-013-7169-7.

    Article  CAS  PubMed  Google Scholar 

  52. Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics. 2016;13(1):70–83. https://doi.org/10.1007/s13311-015-0400-8.

    Article  CAS  PubMed  Google Scholar 

  53. Ellwardt E, Ellwardt L, Bittner S, Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflammation. 2018;5(4):e463. https://doi.org/10.1212/nxi.0000000000000463.

    Article  Google Scholar 

  54. Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, et al. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. J Neurol Sci. 2017;372:92–6. https://doi.org/10.1016/j.jns.2016.11.016.

    Article  CAS  PubMed  Google Scholar 

  55. Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, et al. Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study. J Neurol Sci. 2017;373:335–8. https://doi.org/10.1016/j.jns.2017.01.025.

    Article  CAS  PubMed  Google Scholar 

  56. Choi S-J, Kim B, Lee H-J, Kim S-J, Kim S-M, Sung J-J. Rebound of relapses after discontinuation of rituximab in a patient with MOG-IgG1 positive highly relapsing optic neuritis: a case report. BMC Neurol. 2018;18(1). https://doi.org/10.1186/s12883-018-1222-1.

  57. Nagashima M, Osaka H, Ikeda T, Matsumoto A, Miyauchi A, Kaneko K, et al. Rituximab was effective for acute disseminated encephalomyelitis followed by recurrent optic neuritis with anti-myelin oligodendrocyte glycoprotein antibodies. Brain and Development. 2018;40(7):607–11. https://doi.org/10.1016/j.braindev.2018.03.011.

    Article  PubMed  Google Scholar 

  58. Poupart J, Giovannelli J, Deschamps R, Audoin B, Ciron J, Maillart E, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020. https://doi.org/10.1212/wnl.0000000000009245.

  59. Whittam D, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Dodd J, Brandt A et al. Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (S13.003). Neurology. 2018;90(15 Supplement):S13.003.

  60. Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol. 2019;87:256–66. https://doi.org/10.1002/ana.25648.

    Article  CAS  PubMed  Google Scholar 

  61. Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251. https://doi.org/10.1016/j.msard.2020.102251.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler J. 2016;23(10):1377–84. https://doi.org/10.1177/1352458516678474.

    Article  CAS  Google Scholar 

  63. Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders. Neurol Neuroimmunol Neuroinflammation. 2020;7(3):e705. https://doi.org/10.1212/NXI.0000000000000705.

    Article  Google Scholar 

  64. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66–72. https://doi.org/10.1016/j.msard.2018.07.025.

    Article  PubMed  Google Scholar 

  65. • Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation. 2019;16(1). https://doi.org/10.1186/s12974-019-1525-1. A large retrospective study evaluating rituximab, MMF, and azathioprine in relapsing MOG-AD.

  66. Peschl P, Schanda K, Zeka B, Given K, Böhm D, Ruprecht K et al. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation. 2017;14(1). https://doi.org/10.1186/s12974-017-0984-5.

  67. Hayward-Koennecke H, Reindl M, Martin R, Schippling S. Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis. Neurology. 2019;92(16):765–7. https://doi.org/10.1212/WNL.0000000000007312.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Duke University, DUMC 2905, Durham, NC, 27710, USA

    Petra Brayo MD & Suma Shah MD

Authors
  1. Petra Brayo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suma Shah MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petra Brayo MD.

Ethics declarations

Conflict of Interest

Petra Brayo declares that she has no conflict of interest. Suma Shah declares that she has no conflict of interest. Suma Shah reports personal fees from Biogen, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neurologic Ophthalmology and Otology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brayo, P., Shah, S. MOG-IgG Associated Disease (MOG-AD) in Adults. Curr Treat Options Neurol 23, 17 (2021). https://doi.org/10.1007/s11940-021-00672-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11940-021-00672-6

Keywords

Search

Navigation